Annals of Inquiry

Can a “Living Drug” Cure Autoimmune Diseases?

“活体药物”能否治愈自身免疫性疾病?
CAR-T was developed as a cancer treatment. Now it is showing promise for conditions that have long been considered incurable, such as lupus and multiple sclerosis.
CAR-T疗法最初是为治疗癌症而开发的。如今,它在狼疮和多发性硬化症等长期被视为不治之症的领域展现出治疗潜力。
Cells the body immune system synthetic
Illustration by Petra Péterffy

When Talaya Reid was in high school, in a quiet suburb of Philadelphia, she developed fatigue so severe that she spent afternoons napping instead of going out with friends. She was lethargic at school and her grades suffered, but after graduation she enrolled in community college, where she did well enough to transfer to Temple University. Then, in the summer of 2017, when Reid was twenty-one, she noticed a rash on her face after a day at the beach. Her doctor dismissed it as nothing serious. The rash persisted, so she sought care from a dermatologist, who raised a more ominous possibility: lupus, a disease in which the immune system mistakenly attacks the skin, joints, and internal organs. Blood tests confirmed the diagnosis.

塔拉娅·里德在费城一处安静的郊区读高中时,出现了严重的疲劳症状,每天下午都昏昏欲睡,无法与朋友外出。她在学校无精打采,成绩一落千丈,但毕业后仍考入社区大学,并以优异成绩转入天普大学。2017年夏天,二十一岁的里德在海滩游玩后,发现脸上起了皮疹。医生认为并无大碍。皮疹持续不退,她转而求诊皮肤科医生,却得到一个更不祥的可能:狼疮。这是一种免疫系统错误攻击皮肤、关节及内脏的疾病。血液检测最终确认了这一诊断。

Reid didn’t notice any other symptoms until, a few months later, she awoke with a searing pain in her abdomen. She drove to the E.R., where doctors found protein in her urine—a sign that lupus was affecting her kidneys. She spent eleven days in the hospital being pumped full of medications; by the time she was ready to go home, her body was engorged with twenty pounds of extra fluid, a result of her kidney disease and the steroids used to treat it. Her friends had always known her for her taste in fashion, but now she couldn’t fit into her clothes. “My feet were so swollen, I had to buy shoes two sizes bigger,” she told me.

直到几个月后,里德才注意到其他症状,她醒来时腹部剧痛难忍。她开车去了急诊室,医生在她的尿液中发现了蛋白质——这是狼疮影响肾脏的迹象。她在医院住了十一天,接受了大量药物治疗;等到可以出院时,由于肾病和用于治疗的类固醇药物,她的身体积聚了二十磅的多余液体。朋友们一直欣赏她的时尚品味,但现在她连自己的衣服都穿不进去了。“我的脚肿得厉害,不得不买大两码的鞋子,”她告诉我。

Lupus, which afflicts some five million people worldwide, is a leading cause of death among young women. Doctors had little to offer Reid beyond steroids, which reduce inflammation but can cause bone fractures and diabetes, and a select few immunosuppressant drugs, which expose patients to infections and often fail to halt the disease’s progression. During a medical leave of absence from school, Reid’s hair fell out in fist-sized clumps. The rash on her face left behind scars when it healed. Her joints ached, and her legs were frequently taut with fluid. Throughout college, Reid’s medications provided fleeting relief, followed by relapses that left her bedridden at home. “During the times when my flares were really bad, I’d ask my mom, ‘Can you just lay here with me until I fall asleep?’ ” Reid told me. “Then she could call 911 in case I stopped breathing.”

狼疮在全球范围内困扰着约五百万人,是导致年轻女性死亡的主要原因之一。除了类固醇和少数几种免疫抑制剂,医生对里德几乎无计可施。类固醇能减轻炎症,但可能导致骨折和糖尿病;免疫抑制剂则使患者易受感染,且往往无法阻止病情恶化。休学病假期间,里德的头发大把大把地脱落,脸上的皮疹愈合后留下了疤痕。她关节疼痛,双腿常因积液而紧绷。整个大学期间,药物带来的缓解总是转瞬即逝,随后病情复发,令她卧床不起。“病情严重发作时,我会求妈妈:‘你能躺在这儿陪我睡着吗?’”里德告诉我,“这样万一我停止呼吸,她就能立刻拨打911。”

Reid’s lowest point came in early 2023, when she received an infusion of yet another medication. She, her mother, and her father listened as her nephrologist, Abdallah Geara, explained that her kidneys were still leaking protein. She would eventually need dialysis. “I remember my parents and doctor just kind of pleading with me to keep going,” she told me. “We were all in tears.”

里德的最低谷出现在2023年初,当时她接受了另一种药物的输注。她、她的母亲和父亲听着她的肾病专家阿卜杜拉·吉拉解释说,她的肾脏仍在泄漏蛋白质。她最终将需要透析。“我记得我的父母和医生只是恳求我坚持下去,”她告诉我。“我们都哭了。”

Geara had recently heard about clinical trials for an emerging lupus treatment. In Nature Medicine, a team of German physicians had reported that five patients with severe lupus had received a one-time infusion of CAR-T cells, a therapy previously reserved for certain blood cancers. CAR-T cells are a “living drug” that scientists create by extracting T cells from the patient’s immune system, genetically reprogramming them to destroy specific cells, and infusing them back into the body. (In the case of lupus, the targets are malfunctioning B cells.) Remarkably, the patients in the German study had experienced an immune transformation. Months after treatment, they had essentially no signs of lupus activity in their blood and were able to stop taking medications for the condition.

吉拉最近听说了一种新兴狼疮疗法的临床试验。德国一个医生团队在《自然医学》杂志上报告称,五名重症狼疮患者接受了一次性CAR-T细胞输注治疗——这种疗法此前仅用于某些血液癌症。CAR-T细胞是一种“活体药物”,科学家通过提取患者免疫系统中的T细胞,对其进行基因重编程以摧毁特定细胞,再将其输回体内制成。(针对狼疮的情况,其靶向目标是功能异常的B细胞。)值得注意的是,德国研究中的患者经历了免疫系统的转变。治疗数月后,他们血液中基本检测不到狼疮活动迹象,并且能够停止服用相关药物。

Geara called a colleague at UMass Memorial Medical Center, where a CAR-T trial for lupus was taking place, and learned that a single patient slot remained open. He warned Reid that CAR-T would require chemotherapy to clear out existing immune cells to make space for the modified cells to settle in and proliferate. “He told me I could die from the therapy,” she said. “But if I didn’t get my lupus under control then that could kill me, too.” In March, 2024, Reid travelled to UMass for treatment. As she tapered off the medications she’d been using at home, in preparation for the new therapy, she spiked a fever and her blood counts plummeted. Her lupus was flaring.

吉拉联系了麻省大学纪念医学中心的一位同事,那里正在进行针对狼疮的CAR-T疗法试验,他得知还有一个患者名额空缺。他提醒里德,CAR-T疗法需要化疗来清除现有的免疫细胞,为改造后的细胞腾出空间,使其能够定植并增殖。“他告诉我,我可能会死于这种疗法,”她说。“但如果我不能控制住狼疮,那同样会要了我的命。”2024年3月,里德前往麻省大学接受治疗。当她逐渐减少在家使用的药物,为新的疗法做准备时,她突然发烧,血细胞计数急剧下降。她的狼疮发作了。

Her doctors now had to choose between prioritizing Reid’s immediate health—by removing her from the trial—or by giving Reid steroids that could jeopardize the infusion’s success. In the end, they chose to give her the drugs and then proceed. The steroids helped Reid’s lupus. After the infusion, however, she reacted to the modified cells. She had fevers for eight straight days, and her eyes became red and intensely painful. She was experiencing cytokine storm, a known side effect of CAR-T therapy which can, in some cases, prove fatal. She remained in the hospital for twenty-two days.

如今,医生们面临抉择:是优先考虑里德的即时健康——让她退出试验,还是给她使用可能危及输注成功的类固醇。最终,他们决定先用药再继续治疗。类固醇缓解了里德的狼疮症状。然而输注后,她对改造后的细胞产生了反应。连续八天高烧不退,双眼通红剧痛——她正经历着细胞因子风暴,这是CAR-T疗法已知的副作用,在某些情况下可能致命。她在医院整整住了二十二天。

Autoimmune conditions are probably as ancient as humanity. Descriptions of lupus date back at least to the Middle Ages; its name comes from the Latin word for “wolf,” an allusion to bite-like skin lesions. Queen Anne, the eighteenth-century British monarch, appears in portraits with what looks like a telltale “butterfly rash” on her face, strongly suggesting that she had the condition. But autoimmune conditions were essentially untreatable until the nineteen-forties, when scientists discovered that steroids could reduce inflammation and improve symptoms. Steroids cause numerous side effects that make their long-term use problematic, however. Doctors eventually repurposed chemotherapies and transplant medications (which suppress the immune system)—but these treatments often caused severe infections, cancer, or infertility.

自身免疫性疾病很可能与人类一样古老。狼疮的描述至少可以追溯到中世纪,其名称源于拉丁语中的“狼”,暗指其咬痕般的皮肤病变。十八世纪英国君主安妮女王的肖像中,面部可见典型的“蝶形红斑”,强烈暗示她患有此病。但直到二十世纪四十年代,科学家发现类固醇能减轻炎症、改善症状前,这类疾病基本无药可医。然而类固醇会引发诸多副作用,使其长期使用成为难题。医生们后来将化疗药物和移植抗排异药物(具有免疫抑制作用)转用于治疗,但这些疗法常导致严重感染、癌症或不育。

As a rheumatologist at Columbia University Medical Center, I routinely care for patients with autoimmune diseases. I’m grateful that, in recent years, biologics such as Humira, Enbrel, and Xeljanz—synthesized molecules designed to target specific immune pathways—have been effective against conditions like rheumatoid arthritis, psoriasis, and inflammatory bowel disease. But biologics sometimes don’t work well for lupus, likely because the disease causes such a wide range of symptoms and affects multiple immune pathways. Survival rates for lupus climbed between the nineteen-forties and the nineties, but they have largely plateaued. Women develop the disease in much higher numbers than men; severe cases disproportionately affect Black and Hispanic patients. A person diagnosed before age forty is twelve times as likely to die prematurely as someone without the condition. “I go to fewer funerals these days,” Anca Askanase, a colleague who directs the Columbia Lupus Center, told me. “But there are still too many.”

作为哥伦比亚大学医学中心的风湿病学家,我日常诊治自身免疫性疾病患者。近年来,像修美乐、恩利和捷抑炎这类生物制剂——通过合成分子靶向特定免疫通路——对类风湿关节炎、银屑病和炎症性肠病等疾病疗效显著,我对此心怀感激。但生物制剂对狼疮往往效果不佳,这可能是因为该病症状广泛且涉及多重免疫通路。狼疮存活率在二十世纪四十年代至九十年代间有所提升,但此后基本停滞不前。女性患病率远高于男性;重症患者中黑人和拉丁裔比例异常偏高。四十岁前确诊的患者过早死亡概率是健康人群的十二倍。“这些年我参加的葬礼少了些,”哥伦比亚狼疮中心主任、我的同事安卡·阿斯卡纳斯告诉我,“但依然太多。”

T cells are the foot soldiers of the immune system, capable of identifying threats and mounting attacks. In the eighties, Michel Sadelain, a French-born graduate student in Canada, wondered if T cells could be instructed to kill cancer cells. The answer was yes, but with limitations: T cells rely on a molecule called HLA to recognize targets, and cancers can avoid detection by limiting their expression of HLA.

T细胞是免疫系统的步兵,能够识别威胁并发起攻击。八十年代,在加拿大攻读研究生的法裔学者米歇尔·萨德兰思考能否引导T细胞杀死癌细胞。答案是肯定的,但存在局限:T细胞依赖一种名为HLA的分子识别目标,而癌细胞可通过限制HLA表达来逃避免疫监视。

In the late eighties, an Israeli scientist named Zelig Eshhar successfully fused a T-cell receptor with an antibody, which could recognize cancer cells without relying on HLA. Eshhar’s “T bodies” could bind to tumors, but they were weak and short-lived. Sadelain addressed this problem by engineering a molecule that he called a chimeric antigen receptor (CAR), which activated the T cell’s internal engine, stimulating it to survive and kill repeatedly. He also programmed his CAR-T cells to target CD19, a marker found on nearly all B cells, including those involved in many blood cancers.

八十年代末,一位名叫泽利格·埃沙尔的以色列科学家成功将T细胞受体与抗体融合,这种融合体能够在不依赖HLA的情况下识别癌细胞。埃沙尔的“T体”虽能与肿瘤结合,但作用微弱且寿命短暂。萨德兰通过设计一种他称之为嵌合抗原受体(CAR)的分子解决了这一问题,这种分子能激活T细胞的内在工作机制,促使其持续存活并反复杀伤癌细胞。他还为CAR-T细胞设定了靶向CD19的程序——这种标记物存在于几乎所有B细胞表面,包括与多种血癌相关的恶性B细胞。

In 2010, Bill Ludwig, a sixty-five-year-old with a terminal form of leukemia, became one of the first patients treated with CAR-T cells. The infusion initially left him critically ill: like Reid, he experienced cytokine storm. But, after the storm passed, he was cancer-free until he died, in 2021, of COVID-19 pneumonia. The F.D.A. went on to approve seven CAR-T products, and cellular therapies became a transformative option for tens of thousands of cases of treatment-resistant blood cancers. (They are not without side effects: in November, 2023, the F.D.A. announced that nineteen recipients of CAR-T cancer therapies had reported new T-cell cancers, and the agency now recommends that patients be monitored for life.)

2010年,六十五岁的比尔·路德维希罹患晚期白血病,成为首批接受CAR-T细胞疗法的患者之一。输注治疗最初使他病情危重:与里德相似,他经历了细胞因子风暴。但当风暴平息后,他的癌症完全消失,直至2021年因新冠肺炎去世。美国食品药品监督管理局随后批准了七种CAR-T产品,细胞疗法由此成为数万例耐药性血癌患者的革命性选择。(这种疗法并非全无副作用:2023年11月,FDA通报称有19名接受CAR-T治疗的患者报告了新发T细胞癌,该机构现建议对患者进行终身监测。)

CAR-T’s lupus breakthrough came in 2021, when Georg Schett, a physician at the University of Erlangen-Nürnberg, in Germany, met a young woman with life-threatening lupus who had exhausted all available treatments. Schett had little to offer except an experimental CAR-T therapy, which had appeared to work in mouse models of lupus. The patient agreed, and within weeks of her infusion she was in full remission—a recovery that Schett had never seen before. “It was our eureka moment,” he told me.

CAR-T疗法在狼疮治疗上的突破发生在2021年。当时,德国埃尔朗根-纽伦堡大学的医生格奥尔格·舍特遇到了一位年轻女性狼疮患者,她的病情已危及生命,且所有可用疗法都已用尽。舍特几乎无计可施,只能提供一种实验性CAR-T疗法,该疗法在狼疮小鼠模型中似乎有效。患者同意了,输注几周后,她的病情完全缓解——这是舍特从未见过的康复效果。“那是我们的顿悟时刻,”他告诉我。

Schett and his team treated more lupus patients. Romy Kandera, who received an infusion at eighteen years old, had been a talented pianist until lupus caused swelling in her fingers. While learning a Chopin piece that spanned several octaves, she realized that she could not reach the notes. “Playing music made me special, and I felt like with lupus I was losing that,” she told me. Yet since her CAR-T therapy, in January, 2022, she has been in a drug-free remission. She is now a student in Düsseldorf, and in her free time she has returned to playing piano.

舍特和他的团队治疗了更多狼疮患者。罗米·坎德拉18岁时接受输注,她曾是一位才华横溢的钢琴家,直到狼疮导致手指肿胀。在学习一首横跨数个八度的肖邦曲目时,她意识到自己无法触碰到那些音符。“演奏音乐让我与众不同,而我觉得狼疮正在夺走这一切,”她告诉我。然而,自2022年1月接受CAR-T疗法以来,她已进入无需用药的缓解期。如今她是杜塞尔多夫的一名学生,闲暇时已重拾钢琴演奏。

CAR-T treatments for lupus may not work in every patient, George Tsokos, the chief of rheumatology at Beth Israel Deaconess Medical Center, told me. “No two lupus patients are alike,” he said. “Everybody has their own disease.” He also cautioned that “the experience from treating cancer patients cannot just be transferred over to patients with autoimmune disease.” Our immune systems remain complex and mysterious; they are defined not only by our immune cells but also by our genes and our environments, which are unchanged by CAR-T therapy.

贝斯以色列女执事医疗中心的风湿病科主任乔治·措科斯告诉我,CAR-T疗法可能无法对所有狼疮患者都有效。“没有两个狼疮患者是完全一样的,”他说,“每个人的病情都不同。”他还提醒说,“治疗癌症患者的经验不能直接照搬到自身免疫性疾病患者身上。”我们的免疫系统依然复杂而神秘;它们不仅由免疫细胞决定,还受到基因和环境的影响,而CAR-T疗法无法改变这些因素。

Still, CAR-T is showing promise for a host of other autoimmune conditions. Patients with myositis, an immune disease that attacks muscle, have shown significant improvements in strength. Patients with autoimmune hemolytic anemia, a condition that destroys red blood cells and requires repeated transfusions, saw their blood counts return to normal and were able to stop their medications. Early-stage trials for multiple sclerosis and myasthenia gravis have been similarly encouraging. The list of potential applications has even transcended cancers and autoimmune diseases: preclinical studies are evaluating CAR-T for conditions caused by chronic inflammation, such as cirrhosis and atherosclerosis. CAR-T therapy approaches disease differently than any treatment that came before it. It does not rely on a synthesized chemical to suppress the immune system. Instead, it reprograms the system so that it can help heal itself. “We are seeing that CAR-T cells can do things that conventional medicines have never been able to do,” Sadelain told me. CAR-T also epitomizes personalized medicine: each infusion is specifically designed for the patient who receives it.

尽管如此,CAR-T疗法在其他多种自身免疫性疾病中也展现出广阔前景。患有肌炎(一种攻击肌肉的免疫性疾病)的患者肌力得到显著改善;自身免疫性溶血性贫血(一种破坏红细胞、需要反复输血的疾病)患者的血细胞计数恢复正常并得以停药。针对多发性硬化症和重症肌无力的早期试验同样令人鼓舞。其潜在应用范围甚至已超越癌症和自身免疫疾病领域——临床前研究正在评估CAR-T对肝硬化、动脉粥样硬化等慢性炎症引发疾病的疗效。与传统疗法不同,CAR-T疗法不依赖合成化学物质抑制免疫系统,而是通过重编程让免疫系统实现自我修复。“我们发现CAR-T细胞能完成传统药物从未实现的治疗目标,”萨德兰告诉我。这种疗法也堪称个性化医疗的典范——每一剂输注液都是为特定患者量身定制的。

After Talaya Reid’s weeks in the hospital for the CAR-T trial, she was discharged to a nearby hotel, where she spent a month continuing to recover. To her surprise, her joint pain, fatigue, and swelling all slowly receded. “It was amazing,” she told me. “I felt like I no longer had lupus.” In the two years since then, her lupus has remained in remission without any drugs. Today, she goes to work—she earned a biology degree and is employed by a pharmaceutical company—and travels without thinking about her disease, which had dominated her daily existence for so long.

在塔拉娅·里德因CAR-T疗法试验住院数周后,她被转至附近酒店继续休养一个月。令她惊讶的是,关节疼痛、疲劳和肿胀都逐渐消退。“这太神奇了,”她告诉我,“我感觉自己不再患有狼疮了。”此后两年间,她的狼疮始终处于缓解状态,无需任何药物维持。如今她重返职场——她已获得生物学学位,受聘于一家制药公司——外出旅行时也不再惦记这个曾长期主宰她日常生活的疾病。

In January, I met with Reid and her family at an Italian restaurant not far from their Pennsylvania home. Over dinner, her father, Maurice, recalled how bad her lupus became. “A physical therapist once timed Talaya walking from here”—he gestured to our table—“to there.” He pointed to a spot about ten feet away. “They said she couldn’t move any faster than an eighty-year-old.” Later, when leaving the restaurant, I watched Reid rise from her chair and briskly fall into step with her twenty-four-year-old brother. “I used to look at Talaya’s face and see if it was swollen, which was a bad sign,” her mother, Francine, told me. “I don’t have to do that anymore.”

一月,我在离里德宾夕法尼亚家不远的一家意大利餐厅见到了她和她的家人。席间,她的父亲莫里斯回忆起她的狼疮曾严重到何种地步。“一位理疗师曾给塔拉雅计时,看她从这里走到那里需要多久。”他指了指我们的餐桌,又指向大约十英尺外的一个地方。“他们说她的行动速度比八十岁老人还慢。”后来离开餐厅时,我看着里德从椅子上起身,轻快地跟上她二十四岁弟弟的步伐。“我以前总要观察塔拉雅的脸是否浮肿,那是病情恶化的征兆,”她的母亲弗朗辛告诉我,“现在再也不需要这样了。”

One of the greatest strengths of CAR-T therapy—that each treatment is manufactured for a specific patient—also creates a dilemma. I recently visited the Columbia Initiative in Cell Engineering and Therapy (CICET), where CAR-T cells are produced at my hospital. The ceilings, floors, and walls were glaringly white under harsh fluorescent lights; the air was completely still. I felt as though I was on a space station. Yongzeng Wang, the facilities director, told me that technicians wear hazmat suits and handle only one patient’s cells at a time, to avoid cross contamination. CICET happens to be down the street from Columbia Medical Center, but most manufacturing facilities are far from the hospitals where patients are treated. A patient’s cells must be transported from the hospital to the facility, and the bespoke cells must make the return journey, within narrow treatment windows.

CAR-T疗法最大的优势之一——为特定患者量身定制治疗方案——也带来了一个难题。最近我参观了哥伦比亚细胞工程与治疗计划中心,那里正是我所在医院生产CAR-T细胞的地方。在刺眼的荧光灯下,天花板、地板和墙壁都白得晃眼;空气完全静止。我感觉自己仿佛置身于空间站。设施负责人王永增告诉我,技术人员穿着防护服,每次只处理一位患者的细胞,以避免交叉污染。该中心恰好位于哥伦比亚医学中心的街对面,但大多数制造设施都远离患者接受治疗的医院。患者的细胞必须从医院运送到制造设施,而定制细胞又必须在有限治疗窗口期内完成返程运输。

CAR-T cells are so complex to produce that they typically retail for hundreds of thousands of dollars, according to Ran Reshef, the director of the cellular-therapy program at Columbia Medical Center. The total cost of therapy, including hospitalization, can reach two and a half million dollars per patient in extreme cases. In clinical trials, pharmaceutical companies typically foot the bill, but, when the therapy is approved for specific indications, insurance companies or patients have to absorb the cost. As long as CAR-T cells remain an expensive and scarce resource, there will be difficult questions about who receives them. Askanase, of the Columbia Lupus Center, told me that clinical-trial participants must be sick enough to warrant treatment but healthy enough to survive the therapy. One recent candidate was ideal from a medical standpoint but, as a single mother, could not find child care for when she would need to be in the hospital. “We want to help every patient, and it’s heartbreaking to tell someone no,” Askanase said. For now, that is what many patients will be hearing.

哥伦比亚医学中心细胞疗法项目主任兰·雷谢夫说,CAR-T细胞的生产过程非常复杂,通常零售价高达数十万美元。在极端情况下,包括住院在内的治疗总费用可能达到每名患者250万美元。在临床试验中,制药公司通常会承担费用,但当该疗法被批准用于特定适应症时,保险公司或患者必须承担费用。只要CAR-T细胞仍然是一种昂贵且稀缺的资源,关于谁应该接受治疗的问题就会很棘手。哥伦比亚狼疮中心的阿斯卡纳斯告诉我,临床试验的参与者必须病情严重到需要治疗,但又必须足够健康以承受治疗。最近有一位候选者从医学角度来看是理想的,但作为一位单身母亲,她无法在需要住院时找到人照顾孩子。“我们想帮助每一位患者,拒绝别人是令人心碎的,”阿斯卡纳斯说。目前,许多患者将听到这样的答复。

Reshef is hopeful that alternative methods for producing CAR-T cells may make therapy cheaper and easier. In clinical trials, doctors have treated some patients with allogeneic CAR-T products, which are made from the cells of healthy donors and can be used for more than one patient. Physicians have also been able to reprogram T cells while they are still in the patient’s body, an approach that eliminates the need for specialized cell-processing plants. Either approach could cut costs and democratize access, but it’s too soon to know if they will produce the same results as existing CAR-T treatments.

雷谢夫希望,替代性的CAR-T细胞生产方法或许能让治疗变得更便宜、更简单。在临床试验中,医生已用异体CAR-T产品治疗部分患者,这些产品源自健康捐赠者的细胞,可供多名患者使用。医生们还实现了在患者体内直接重编程T细胞,这种方法无需依赖专业细胞处理工厂。无论哪种途径都可能降低成本、普及治疗,但目前尚无法判断它们能否达到现有CAR-T疗法的同等效果。

CAR-T therapy is already changing what doctors and patients consider possible, however. When I spoke with Schett, of Erlangen-Nürnberg, he pointed out that patients have always come to physicians with a straightforward hope: that their diseases can be cured. Yet doctors who treat autoimmune diseases have historically avoided that kind of language. “We have so much adapted to the idea that the patient with autoimmune disease is a patient forever—which is total nonsense,” Schett told me. “We should be courageous to say: if after five years a patient really has no flare, no relapse, and no therapy, then this might be a cure.” ♦

然而,CAR-T疗法正在改变医生和患者对可能性的认知。当我与来自埃尔朗根-纽伦堡的舍特交谈时,他指出,患者向来带着一种朴素的期望求医:他们的疾病能够被治愈。然而,治疗自身免疫性疾病的医生历来避免使用这类表述。“我们太习惯于认为自身免疫性疾病患者将终身患病——这完全是谬误,”舍特告诉我,“我们应该有勇气宣告:如果患者在五年后确实没有发作、没有复发、且无需治疗,那么这或许就是治愈。” ♦

2 free previews left — register to get 30 translations a month